Avid Bioservices, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Avid Bioservices, Inc. (NASDAQ:CDMO; OTC:CDMOP) operates as a dedicated contract development and manufacturing organization (CDMO) focused on biologics for the biotechnology, biopharmaceutical, and cell and gene therapy industries. The company provides comprehensive process development services, including cell line development, upstream and downstream process optimization, analytical methods development, and product characterization; current good manufacturing practice (CGMP) clinical and commercial drug substance manufacturing for mammalian proteins such as monoclonal antibodies, enzymes, and recombinant proteins in batch, fed-batch, and perfusion modes using bioreactor scales from 50L to 2,000L across five dedicated production suites; bulk packaging; release and stability testing; and regulatory submission support. Avid Bioservices serves clients primarily in the United States from its headquarters and state-of-the-art facilities at 14191 Myford Road, Tustin, California. Founded in 1981 as Peregrine Pharmaceuticals, Inc. and rebranded to Avid Bioservices, Inc. in 2018 upon becoming an independent entity listed on NASDAQ, the company has over 30 years of experience in biologics manufacturing, including its first FDA commercial approval in 2005 and the commissioning of its mammalian protein CGMP Drug Substance Line 3 facility in 2023. In a major strategic development, Avid Bioservices was acquired in February 2025 by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion, following a definitive merger agreement announced in November 2024; this partnership positions the company for accelerated growth through expanded service offerings, talent investment, technological enhancements, and greater geographic reach in the CDMO sector. Under new leadership, including President and CEO Kenneth Bilenberg, Avid Bioservices emphasizes agility, reshoring support, and patient-centered biologics manufacturing to meet evolving client needs. The acquisition builds on the company's annual manufacturing capacity exceeding 4,000 liters and its track record of delivering high-quality CGMP products.
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
Avid Stockholders Approve Transaction with GHO and Ampersand
Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand
Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand
Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
Avid Bioservices to Participate at Upcoming Investor Conferences
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes